Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader
Source ↗
👁 0
💬 0
The post Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader appeared first on 24/7 Wall St..
Quick Read
Eli Lilly (LLY) reported Q4 revenue of $19.29B up 42.6% YoY, with Mounjaro generating $7.41B (up 110%) and Zepbound adding $4.26B (up 123%).
Novo Nordisk (NVO) posted Q4 revenue down 7.6% YoY and cut 9,000 jobs as it warned
Quick Read
Eli Lilly (LLY) reported Q4 revenue of $19.29B up 42.6% YoY, with Mounjaro generating $7.41B (up 110%) and Zepbound adding $4.26B (up 123%).
Novo Nordisk (NVO) posted Q4 revenue down 7.6% YoY and cut 9,000 jobs as it warned
Comments (0)